89Bio operates as a clinical-stage biopharmaceutical company. The company focuses on developing therapies and drugs for treatments of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. The company serves customers in the United States and Israel.

AppFolio provides industry-specific, cloud-based business software solutions, services and data analytics. The company's solutions include: AppFolio Property Manager, a cloud-based software solution that provides tools and services designed to streamline their property management businesses; AppFolio Investment Management, a cloud-based software solution for real estate investment managers of various sizes providing tools and services designed to streamline their real estate investment management businesses; and MyCase, a cloud-based software solution for the legal market that provides small law firms tools and services designed to streamline their legal practice and manage their caseload.

Axcella Health is a biotechnology company pioneering the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. The company's AXA Candidates are generated from its proprietary, human-focused AXA Development Platform and harness the power of endogenous metabolic modulators, or EMMs, a broad family of molecules that fundamentally impact and regulate human metabolism.

AZZ is a provider of galvanizing and metal coating services, welding solutions, specialty electrical equipment and highly engineered services to the power generation, transmission, distribution, refining and industrial markets. The company operates in two segments; Energy, which is engaged in delivering transmission of power from generation sources to end customers, and automated weld overlay solutions for corrosion and erosion mitigation to infrastructure in the energy markets; and Metal Coatings, which is a provider of metal finishing solutions for corrosion protection, including hot dip galvanizing to the North American steel fabrication industry.

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company serves customers in the State of Pennsylvania.

CalAmp is a telematics solutions provider. The company's software applications, cloud services, and intelligent devices collect and assess data including industrial machines, commercial and passenger vehicles, their drivers and contents. The company operates under two reportable segments: Telematics Systems, which provide a series of telematics and stolen vehicle recovery products for the connected vehicle and emerging Internet of Machines marketplace; and Software and Subscription Services, which provide cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open Application Programming Interfaces.

Clear Channel Outdoor Holdings is a holding company. Through its subsidiaries, the company is an outdoor advertising company providing clients with advertising activities through billboards, street furniture displays, transit displays and other out-of-home advertising displays. The company's segments include:, Americas outdoor advertising, which consists of printed and digital billboards, transit displays, including airports, street furniture and wallscapes and other spectaculars; and International outdoor advertising, which includes its operations in Europe, Asia and Latin America and consists of street furniture, billboards, transit displays, retail displays, public bike programs and other spectaculars.

Dave & Buster's Entertainment is an owner and operator of entertainment and dining venues (stores) that operate under the name Dave & Buster's. The company's concept is to provide its customers the opportunity to Eat Drink Play and Watch all in one location for adults and families, while serving food and beverages. The company's Eat and Drink is provided through a menu of entrees and appetizers and a selection of non-alcoholic and alcoholic beverages. The company's Play and Watch offerings provide an assortment of entertainment attractions centered around playing games and watching live sports and other televised events.

Fastenal is engaged in the wholesale distribution of industrial and construction supplies. The company is a distributor of fasteners and related industrial and construction supplies. This includes threaded fasteners, bolts, nuts, screws, studs, and related washers, as well as miscellaneous supplies and hardware, such as pins, machinery keys, concrete anchors, metal framing systems, wire rope, strut, rivets, and related accessories. The company's fastener product line is primarily sold under the Fastenal product name.

Hudson Global provides recruitment and related talent solutions. The company's main service offerings include Recruitment Process Outsourcing (RPO) consisting of RPO Recruitment and RPO Contracting. The company provides recruitment outsourcing, project-based outsourcing, and recruitment consulting for clients' permanent staff hires. The company's RPO Recruitment services utilizes its consultants, supported by its specialists in the delivery of its proprietary methods. RPO Contracting provides RPO clients with a range of outsourced personnel contract staffing services and managed service provider services provided sometimes on a standalone basis and sometimes as part of a blended total talent solution.

JELD-WEN Holding is a holding company. Through its subsidiaries, the company is a door and window manufacturer. The company designs, produces, and distributes a range of interior and exterior doors, wood, vinyl, and aluminum windows, and related products for use in the construction and repair and remodel of residential homes and, to a lesser extent, non-residential buildings. The company markets its products under the JELD-WEN brand, along with several brands such as Swedoor and DANA in Europe and Corinthian, Stegbar, and Trend in Australia. The company's customers include wholesale distributors and retailers as well as individual contractors and consumers. The company has three segments: North America, Europe, and Australasia.

MacroGenics discovers and develops antibody-based therapeutics to modulate the human immune response for the treatment of cancer. The company has a pipeline of product candidates in human clinical testing, including immuno-oncology programs, that have been created using its proprietary antibody-based technology platforms. The company is developing product candidates that target various tumor-associated antigens, including HER2. The company is also developing a franchise of molecules that target programmed cell death protein 1 (PD-1). The company is developing two bispecific DART product candidates that engage PD-1 and lymphocyte-activation gene 3, as well as PD-1 and cytotoxic T-lymphocyte-associated protein 4.

NGM Biopharmaceuticals is a biopharmaceutical company. The company is focused on the following programs: Aldafermin, which is for the treatment of non-alcoholic steatohepatitis (NASH); NGM313 (MK-3655), which is for the treatment of NASH and type 2 diabetes; NGM120, which is designed to block the effects of elevated growth differentiation factor 15 levels on cancer anorexia/cachexia syndrome, and, possibly, tumors; NGM217, which is designed to restore pancreatic islet function and increase insulin production in patients with diabetes; NGM621, which is designed to decrease levels of this protein implicated in the dry form of AMD; and NGM395, which is for the treatment of metabolic syndrome.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

QuinStreet provides marketplace products and technologies. The company focuses on customer acquisition for clients in markets or verticals including financial services, education, home services and business-to-business technology. The company delivers marketing results to its clients, typically in the form of a qualified click, lead, inquiry, call, application, or customer. Clicks, leads, inquiries, calls, and applications can then convert into a customer or sale for clients at a rate that results in an acceptable marketing cost to them. The company is typically paid by clients when it delivers qualified clicks, leads, inquiries, calls, applications, or customers as defined by its agreements with them.

Re/Max Holdings is a holding company. The company's only business is to act as the sole manager of RMCO, LLC. The company is a franchisor in the real estate industry, franchising real estate brokerages globally under the RE/MAX (RE/MAX) brand, and mortgage brokerages within the U.S. under the Motto Mortgage (Motto) brand. RE/MAX and Motto are fully franchised - the company does not own any of the brokerages that operate under these brands. All of the RE/MAX branded brokerage office locations are being operated by franchisees. The company operates under the following three segments: RE/MAX Franchising, Motto Franchising and booj.

Veracyte is a genomic diagnostics company. The company's products include the following: Afirma Genomic Sequencing Classifier and Xpression Atlas, which includes the Afirma GSC and Xpression Atlas; Percepta Bronchial Genomic Classifier, which improves lung cancer diagnosis by improving the performance of diagnostic bronchoscopies; Envisia Genomic Classifier, which improves diagnosis of idiopathic pulmonary fibrosis; and Prosigna Breast Cancer Prognostic Gene Signature Assay, which uses genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease.